Li Mingli, Li Mingxuan, Wei Yangang, Xu Hua
Department of Life Science and Engineering, Jining University, Jining, China.
Nursing Department, Affiliated Hospital of Jining Medical University, Jining, China.
Front Oncol. 2020 Aug 6;10:1202. doi: 10.3389/fonc.2020.01202. eCollection 2020.
Cyclooxygenase-2 (COX-2) is a critical enzyme associated with inflammation and tumorigenesis. Although several studies have compared the expression of COX-2 in endometrial cancer tissues and normal tissues, the results have been inconsistent thus far. This study aims to conduct a meta-analysis to elucidate the role of COX-2 in the determination of the risk, prognosis, and clinical features of endometrial cancer. We retrieved the suitable studies on the association between COX-2 expression and endometrial cancer from PubMed, EMBASE, and Web of Science databases that were published between 1999 and September 31st, 2019. The hazard ratio (HR) and 95% confidence intervals (CIs) were retrieved to assess the relationship between COX-2 expression and the prognosis of endometrial cancer. The odds ratio (OR) and 95% CIs were calculated to evaluate the correlation between COX-2 expression and the risk and clinical features of endometrial cancer. To investigate the association between COX-2 expression and the susceptibility, clinical features, and prognosis of endometrial cancer, we performed a meta-analysis on data from selected studies that collectively involved 273 normal individuals and 1,376 patients with endometrial cancer. Overall, the pooled analysis indicated that COX-2 expression was significantly associated with susceptibility (Caucasians, OR = 3.94, 95% CI = 2.17-7.17, < 0.05; Asians, OR = 20.51, 95% CI = 8.54-49.26, < 0.05), cancer stage (OR = 3.01, 95% CI = 1.95-4.67, < 0.05), myometrial invasion (OR = 1.59, 95% CI = 1.17-2.15, < 0.05), lymph node metastasis (OR = 1.63, 95% CI = 1.18-2.26, < 0.05), and prognosis (OR = 2.91, 95% CI = 1.17-4.66, < 0.05) in endometrial cancer. Our findings suggested that COX-2 overexpression is significantly associated with poor prognosis and advanced clinical features in endometrial cancer. Therefore, COX-2 may function as an effective prognostic biomarker and a potential therapeutic target for endometrial cancer.
环氧化酶-2（COX-2）是一种与炎症和肿瘤发生相关的关键酶。尽管多项研究比较了COX-2在子宫内膜癌组织和正常组织中的表达情况，但迄今为止结果并不一致。本研究旨在进行一项荟萃分析，以阐明COX-2在子宫内膜癌风险、预后及临床特征判定中的作用。我们从PubMed、EMBASE和Web of Science数据库中检索了1999年至2019年9月31日发表的关于COX-2表达与子宫内膜癌关联的合适研究。检索风险比（HR）和95%置信区间（CI）以评估COX-2表达与子宫内膜癌预后的关系。计算比值比（OR）和95%CI以评估COX-2表达与子宫内膜癌风险及临床特征的相关性。为研究COX-2表达与子宫内膜癌易感性、临床特征及预后的关联，我们对所选研究的数据进行了荟萃分析，这些研究共纳入273名正常个体和1376例子宫内膜癌患者。总体而言，汇总分析表明COX-2表达与子宫内膜癌的易感性（高加索人，OR = 3.94，95%CI = 2.17 - 7.17，<0.05；亚洲人，OR = 20.51，95%CI = 8.54 - 49.26，<0.05）、癌症分期（OR = 3.01，95%CI = 1.95 - 4.67，<0.05）、肌层浸润（OR = 1.59，95%CI = 1.17 - 2.15，<0.05）、淋巴结转移（OR = 1.63，95%CI = 1.18 - 2.26，<0.05）及预后（OR = 2.91，95%CI = 1.17 - 4.66，<0.05）显著相关。我们的研究结果表明，COX-2过表达与子宫内膜癌的不良预后和晚期临床特征显著相关。因此，COX-2可能作为子宫内膜癌有效的预后生物标志物和潜在的治疗靶点。
